•
Dec 31, 2024
Janux Q4 2024 Earnings Report
Expected Revenue:$490K
-33.8% YoY
Expected EPS:-$0.49
32.4% YoY
Key Takeaways
Janux Therapeutics reported positive Phase 1 clinical trial data for PSMA-TRACTr JANX007 in mCRPC and raised approximately $402.5 million in gross proceeds from an underwritten offering. The company's cash and cash equivalents and short-term investments reached $1.03 billion at year-end. Net loss for the quarter was $20.2 million.
Presented positive Phase 1 clinical trial data for PSMA-TRACTr JANX007 in mCRPC.
Enrollment is ongoing for JANX007 and JANX008.
An update on JANX007 and JANX008 data is anticipated in 2025.
Year-end cash, cash equivalents, and short-term investments totaled $1.03 billion.
Janux
Janux
Forward Guidance
Janux plans to provide an update on pipeline programs selected for clinical development and will host an R&D Day in 2025.